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Abstract
Introduction Both experimental and clinical data provide
evidence that vitamin D is one of those important environmental
factors that can increase the prevalence of certain autoimmune
diseases such as systemic lupus erythematosus, rheumatoid
arthritis, insulin-dependent diabetes mellitus, and inflammatory
bowel disease. The aim of the present study was to investigate
the prevalence of vitamin D insufficiency in patients with
undifferentiated connective tissue disease (UCTD).
Methods Plasma 25(OH)D3 levels in 161 UCTD patients were
measured in both summer and winter periods. Autoantibody
profiles (antinuclear antibody, anti-U1-ribonucleoprotein, anti-
SSA, anti-SSB, anti-Jo1, anti-Scl70, anti-double-stranded DNA,
anti-centromere, anti-cardiolipin, rheumatoid factor, and anti-
cyclic citrullinated peptide) and clinical symptoms of the
patients were assessed.
Results P l a s m a  l e v e l s  o f  2 5 ( O H ) D 3 in UCTD patients were
significantly lower compared with controls in both summer and
winter periods (UCTD summer: 33 ± 13.4 ng/mL versus control:
39.9 ± 11.7 ng/mL, P = 0.01; UCTD winter: 27.8 ± 12.48 ng/
mL versus control: 37.8 ± 12.3 ng/mL, P  = 0.0001). The
presence of dermatological symptoms (photosensitivity,
erythema, and chronic discoid rash) and pleuritis was
associated with low levels of vitamin D. During the average
follow-up period of 2.3 years, 35 out of 161 patients (21.7%)
with UCTD further developed into well-established connective
tissue disease (CTD). Patients who progressed into CTDs had
lower vitamin D levels than those who remained in the UCTD
stage (vitamin D levels: CTD: 14.7 ± 6.45 ng/mL versus UCTD:
33.0 ± 13.4 ng/mL, P = 0.0001).
Conclusions In patients with UCTD, a seasonal variance in
levels of 25(OH)D3 was identified and showed that these levels
were significantly lower than in controls during the
corresponding seasons. Our results suggest that vitamin D
deficiency in UCTD patients may play a role in the subsequent
progression into well-defined CTDs.
Introduction
Environmental factors play an important role in the develop-
ment and progression of systemic autoimmune diseases along
with susceptible genetic and hormonal background. It has
been suggested recently that vitamin D is an environmental
factor that, by modulating the immune system, affects the prev-
alence of autoimmune syndromes. Thus, vitamin D deficiency
may have a role in the pathogenesis of systemic autoimmune
diseases.
The classic and well-known function of vitamin D is to regulate
mineral homeostasis and thus bone formation and resorption.
On the other hand, a less traditional function of vitamin D has
been demonstrated, including substantial effects on the
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regulation of cell proliferation and differentiation. Also, vitamin
D has been described to modulate immune responses [1-6].
Active vitamin D has been shown to inhibit the differentiation
and maturation of myeloid dendritic cells to reduce the expres-
sion of major histocompatibility complex II, co-stimulatory mol-
ecules (CD80, CD86, and CD40), and the maturation proteins
(CD1a and CD83) [7]. In addition, the antigen-presenting
capacity of macrophages and dendritic cells is suppressed
and the immune stimulatory interleukin-12 (IL-12) is inhibited
by active vitamin D [8]. Th1 and Th2 cells are direct targets of
active vitamin D. Vitamin 1,25(OH)2D3 decreased the prolifer-
ation of Th1 cells and also inhibited the production of IL-2,
interferon-gamma (IFN-γ), and tumor necrosis factor-alpha of
Th1 cells and had an anti-proliferative effect [3,9]. Further-
more, vitamin D silences the Th17 response and also repairs
the number and function of the CD4+/CD25+ regulatory T
cells, which may prevent the development of autoimmune dis-
eases [9,10]. These findings suggest that the effect of vitamin
D is predominantly tolerogenic.
Cantorna and Mahon [11] have shown that vitamin D status as
an environmental factor affects autoimmune disease preva-
lence. The determination of the exact connection is difficult
because of the complexity of the vitamin D regulatory system.
Moreover, complicated interactions could occur between
genes that may affect autoimmune disease susceptibility [11].
Serum levels of vitamin D were significantly lower in systemic
lupus erythematosus (SLE) and insulin-dependent diabetes
mellitus (IDDM) than in the healthy population [12-15].
Recently, it was also found that lower levels of vitamin D were
associated with higher disease activity in rheumatoid arthritis
(RA) [6]. An inverse correlation has been described between
the supplementation of vitamin D and the development of
IDDM and multiple sclerosis (MS) [1,12].
The evolution of diseases with an immune-pathogenetic back-
ground is usually slow and progressive. The term 'undifferenti-
ated connective tissue disease' (UCTD) has been used since
1980 to describe a group of connective tissue diseases
(CTDs) that lack the characteristics of any distinctive disease.
There is great deal of information available regarding the clini-
cal and serological profile of UCTD and the rate of evolution
into well-defined CTD [16-18]. About 30% to 40% of patients
with UCTD will evolve to defined CTD during the years of fol-
low-up. The higher rate of disease evolution can be seen
mostly between the first and second years [18,19]. UCTD has
specific signs and/or autoantibodies that are characteristic of
autoimmune disease. Mosca and colleagues [18,19] and our
previous studies [16] reported that the most frequent clinical
manifestations of UCTD were polyarthralgy/polyarthritis, Ray-
naud phenomenon, serositis (pleuritis and pericarditis), photo-
sensitive rash, xerostomia, and xerophthalmia as well as
central nervous system involvement. During the follow-up
period, new organ manifestations can appear and the existing
clinical and immunological abnormalities can increase in inten-
sity or even become permanent. Evolution to SLE and other
systemic autoimmune diseases (mixed connective tissue dis-
ease [MCTD], systemic sclerosis, Sjögren syndrome, polymy-
ositis/dermatomyositis, RA, and systemic vasculitis) has also
been described.
Until now, there have been no data on the 25(OH)D3 levels in
UCTD patients. The aim of our study was to assess the vitamin
D deficiency in UCTD patients and compare it with controls.
We examined the seasonal variance of the vitamin D levels
during the summer and winter months. We also determined a
possible connection between low levels of vitamin D and the
clinical and serological manifestations of the disease. In addi-
tion, we determined the prevalence of the 25(OH)D3 levels in
patients with UCTD and assessed its probable pathogenic
role in the progression toward a well-defined CTD.
Materials and methods
The study population involved 161 patients (154 women and
7 men) with UCTD followed up with and treated at the Division
of Clinical Immunology, 3rd Department of Internal Medicine,
Medical and Health Science Center, University of Debrecen
(Debrecen, Hungary). All patients with UCTD were enrolled
based on the following criteria: (a) symptoms and signs sug-
gestive of a CTD not fitting the accepted classification criteria
for any of the defined CTDs, (b) disease duration of at least 1
year, and (c) the presence of at least one non-organ-specific
autoantibody. No patients had received corticosteroids or
immune-suppressive or cytotoxic drugs. Patients with a
defined CTD were diagnosed according to the corresponding
American College of Rheumatology classification criteria
[17,18,20-25]. An informed consent form was signed by all
patients approved by the ethics committee of the University of
Debrecen. Age- and gender-matched healthy individuals
served as controls with no autoimmune/endocrine or malig-
nant neoplastic diseases (residents and health care workers).
Clinical data, including age, body mass index, age at diagno-
sis, and therapy, were obtained by a questionnaire or from
patient charts. All patients were followed up with every 4
months. Diagnostic procedures for all patients included chest
x-ray, spirometry/diffusion capacity, Doppler echocardiogra-
phy and high-resolution computed tomography, Schirmer test,
sialometry, and radionuclide esophageal transit scingtigraphy.
Laboratory measurements included erythrocyte sedimentation
rate, full blood count, urine analysis, serum creatine phos-
phokinase, serum calcium, kidney and liver function tests, thy-
roid-stimulating hormone, and parathyroid hormone (PTH).
PTH was measured using an Advia Centaur autoanalyser (Sie-
mens Healthcare Diagnostics, Deerfield, IL, USA) using rea-
gents and protocols provided by the manufacturer. At the time
of study, all patients with UCTD underwent bone densitometry
using a Lunar-DPX-L DEXA instrument (Lunar Radiation Cor-
poration, Madison, WI, USA). Bone mineral density (BMD) of
lumbar 2 to 4 vertebrae and femoral neck was assessed andAvailable online http://arthritis-research.com/content/10/5/R123
Page 3 of 8
(page number not for citation purposes)
T scores were determined. Osteoporosis or least osteopenia
was according to the World Health Organization classification
criteria (T score of less than -1) [26]. All patients and control
subjects had normal mean BMD values. Patients had no signs
of renal insufficiency and did not take any vitamin D supple-
ments prior to or in parallel with the investigations. At diagno-
sis of UCTD, the plasma 25(OH)D3 levels were measured. We
assessed the plasma 25(OH)D3 levels of 161 UCTD patients
and 59 control subjects during the summer (from June to
October) and winter (from January to May) periods.
Immune serological analyses
Antinuclear antibodies were determined by indirect immun-
ofluorescence on HEp-2 cells. Anti-U1-ribonucleoprotein
(anti-U1-RNP), anti-Sm, anti-SSA, anti-SSB, anti-Jo1, anti-
Scl70, and anti-cardiolipin (anti-CL) antibodies were analyzed
in all patients by enzyme-linked immunoabsorbent assay
(ELISA) in accordance with the instructions of the manufactur-
ers (Pharmacia & Upjohn Diagnostics GmbH, Freiburg, Ger-
many, and Cogent Diagnostics Ltd, Edinburgh, UK). IgM
rheumatoid factor (RF) was assessed by nephelometry, and
values greater than 50 U/L were considered positive. Anti-
cyclic citrullinated peptide (anti-CCP) levels were measured
using a second-generation ELISA (Quanta Lite™, CCP ELISA;
Inova Diagnostics, Inc., San Diego, CA, USA) and using syn-
thetic citrullinated peptides bound to the surface of a micro-
titer plate as antigen. The test was performed in accordance
with the manufacturer's instructions. Serum samples, col-
lected immediately after the initial diagnosis of patients, were
separated and stored at -70°C.
Determination of vitamin D levels
Plasma levels of 25(OH)D3 vitamin of patients and controls
were assessed at the Department of Clinical Biochemistry and
Molecular Pathology Laboratory of the University of Debrecen
Medical and Health Science Center. Samples were analyzed
by a high-performance liquid chromatograph (HPLC) method
using the Jasco HPLC system (Jasco, Inc., Easton, MD, USA)
and a Bio-Rad reagents kit (Bio-Rad Laboratories, Inc., Her-
cules, CA, USA). The sample (500 μL of plasma from EDTA
[ethylenediaminetetraacetic acid] anticoagulated blood) was
purified from proteins, and 50 μL of the cleaned supernatant
was injected into the instrument. Separation was achieved
with a reverse-phase C18 Bio-Rad column (90 × 3.2 mm)
(Bio-Rad Laboratories, Inc.). The mobile phase (methanol-
water mixture) had a flow rate of 1.1 mL/minute. For quantita-
tive determination of the separated compound, a diode array
detector (set at 265 nm) was used. According to current rec-
ommendations, plasma 25(OH)D3 levels of less than 30 and
10 ng/mL were defined as vitamin D insufficiency and vitamin
D deficiency, respectively [27-29].
Statistical analysis
Data were presented as a percentage or a mean value ±
standard deviation. GraphPad Software (GraphPad Software,
Inc., San Diego, CA, USA) was used in data interpretation
(two-tailed t test, chi-square test, and Fisher exact test, logistic
regression). A Pierce regression coefficient assay was also
performed when required. Multiple linear regression models
were used to examine the relationship between vitamin D level
clinical signs, smoking, and seasonality. P values of less than
0.05 were considered to be statistically significant.
Results
Clinical and serological data of 161 patients with 
undifferentiated connective tissue disease
The mean age at diagnosis of 161 patients with UCTD was
44.91 ± 12.7 years (women/men: 22:1). The mean duration of
symptoms at the time of enrollment into the study was 4.09 ±
2.36 years. The ratio of women and men was very similar in the
two groups (control group number: 59; mean age: 43.9 ±
15.1 years; women/men: 18:1). There was no difference
between the body weight, height, body mass index, and BMD
values in patients and controls. The most frequent clinical man-
ifestation of UCTD was polyarthritis (28.5%). The frequency of
skin lesions (photosensitivity, erythema, and lymphocytic vas-
culitis) was 22.9%, and the frequency of Raynaud phenome-
non was 17.3%. Xerophthalmia was observed in 15.5% of
patients. Pleuritis (5.59%), neuropathy (4.96%), deep vein
thrombosis (2.48%), myositis (1.2%), and pulmonal manifesta-
tions (1.2%) were less frequent among the first clinical symp-
toms of the patients. The prevalence of dysmotility was 13.6%
in UCTD patients. The most frequent immune serological
abnormality in the serum of patients was the presence of anti-
nuclear antibody, which was found in 64.59% of patients. The
earliest antibody at the onset of UCTD was anti-SSA, which
was present in 43 patients (26.7%). Anti-CL autoantibodies
could be detected in 40 patients (24.8%). Anti-U1-RNP anti-
bodies were found in the sera of 29 patients (18.0%), anti-Sm
antibody in 8 (4.9%), anti-CCP in 14 (8.6%), anti-double-
stranded DNA (anti-dsDNA) in 12 (7.4%), anti-SSB in 9
(5.59%), anti-neutrophil cytoplasmic antibody in 4 (2.48%),
and IgM RF in 2 patients (1.2%) at the initial diagnosis of
UCTD.
Levels of vitamin D in patients with undifferentiated 
connective tissue disease
The summer and winter levels of 25(OH)D3 in patients with
UCTD were significantly lower compared with healthy individ-
uals (UCTD summer: 33.0 ± 13.4 ng/mL versus control: 39.9
± 11.7 ng/mL, P = 0.010; UCTD winter: 27.8 ± 12.48 ng/mL
versus control: 37.8 ± 12.3 ng/mL, P = 0.0001) (Figure 1). In
UCTD patients, the winter levels of vitamin D were considera-
bly lower than the summer levels (UCTD summer: 33.0 ± 13.4
ng/mL, UCTD winter: 27.8 ± 12.48 ng/mL, P = 0.001). In the
control group, vitamin D levels were lower in the winter than in
the summer, but the difference was not significant (controls
summer: 39.9 ± 11.7 ng/mL, controls winter: 37.8 ± 12.3 ng/
mL,  P  = not significant). Hereafter, the summer levels of
25(OH)D3 in controls were used for comparison. There wasArthritis Research & Therapy    Vol 10 No 5    Zold et al.
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vitamin D insufficiency (<30 ng/mL vitamin D level) in 41.6%
of UCTD patients (67 patients) during the summer months, in
54.3% of patients (88 patients) during the winter, and in
18.64% of controls (11 subjects) (Table 1). In UCTD patients
with vitamin D insufficiency, the winter levels of vitamin D were
significantly lower than the summer levels (UCTD [<30 ng/mL]
summer: 21.9 ± 4.7 ng/mL and winter: 18.1 ± 5.9 ng/mL, P =
0.03). Vitamin D deficiency (<10 ng/mL vitamin D level) was
found in 5 of the UCTD cases.
Correlation of clinical and laboratory parameters with 
plasma levels of vitamin D
Dermatological symptoms (photosensitivity, erythema, and
discoid skin lesions) (P = 0.0046) and pleuritis (P = 0.0346)
were also more frequent in UCTD patients with low levels of
vitamin D (<30 ng/mL) (Table 2). Interestingly, patients with
high serum levels of anti-U1-RNP, anti-SSA, and anti-CCP
antibodies were found to have the lowest vitamin D levels (anti-
U1-RNP: P = 0.024, anti-SSA: P = 0.029, and anti-CCP: P =
0.0001). During the follow-up period, 35 out of 161 UCTD
patients (21.7%) developed an established CTD (Figure 2).
The evolution to defined CTD was an average of 2.3 ± 1.2
years. Among these patients, 12 developed RA, 6 SLE, 6
MCTD, 6 Sjögren syndrome, 2 systemic vasculitis, and 3
antiphospholipid syndrome. Surprisingly, we found the lowest
significant levels of vitamin D in those patients who eventually
developed CTD compared with patients who remained in the
UCTD stage (established CTD patients: 14.7 ± 6.45 ng/mL,
remained in the UCTD stage: 33.0 ± 13.4 ng/mL, P = 0.0001)
(Table 3).
Discussion
Epidemiological studies suggest that the development of sys-
temic autoimmune disease is affected by geographical areas
and lifestyle. Presumably, in these processes, vitamin D is a
significant environmental factor. Vitamin D deficiency has been
linked to several different diseases, including malignant and
immune-pathogenetic disorders. Age, gender, lifestyle, geo-
graphical areas, sunlight, and vitamin D supplementation are
important determinants of vitamin D levels. In countries with
temperate climates, such as Hungary, serum vitamin D con-
centrations rise and fall throughout each year in parallel with
sun exposure [30-33]. The prevalence of vitamin D deficiency
is much higher in Europe than in Asia, Australia, or the US. In
Hungary, a high prevalence of hypovitaminosis D in healthy
postmenopausal women has been described [34].
In the present study, we first analyzed the circulating levels and
seasonal variance in the levels of 25(OH)D3 in a large cohort
of patients with UCTD. According to our studies, in UCTD
patients, vitamin D levels were significantly lower than in the
control group both during the summer and winter months. Cir-
culating levels of vitamin D fluctuate seasonally in UCTD
patients, with low levels of 25(OH)D3 in the winter months and
high levels during the summer months. Our data suggested
that patients with UCTD have vitamin D insufficiency in 41%
of cases in the summer months and even more became vitamin
D-deficient during the wintertime. In UCTD patients, the winter
levels of vitamin D were considerably lower than the summer
levels. Plasma levels of 25(OH)D3 in UCTD patients were sig-
nificantly lower compared with controls both in summer and
winter periods. Vitamin D deficiency was found in 5 of the
UCTD cases (3.1%) compared with none in the control group.
Figure 1
Comparison of vitamin D of undifferentiated connective tissue disease  (UCTD) patients with healthy controls during the summer and winter  months Comparison of vitamin D of undifferentiated connective tissue disease 
(UCTD) patients with healthy controls during the summer and winter 
months. NS, not significant.
Table 1
Seasonal fluctuation of the levels of vitamin D in patients with undifferentiated connective tissue disease
UCTD patients
Summer
n = 161
UCTD patients
Winter
n = 161
Control
Summer
n = 59
Vitamin D insufficiency (<30 ng/mL) 67 patients (41.6%)
21.0 ± 5.79a
88 patients (54.3%)
18.4 ± 6.7b
11 (18.64%)
25.0 ± 4.65c
Vitamin D deficiency (<10 ng/mL) 5 (3.1%)
(1 RA, 4 UCTD)
5 (3.1%)
(2 RA, 3 UCTD)
Significance: a-csummer-control: P = 0.14; b, cwinter-control: P = 0.016; a, bsummer-winter: P = 0.03. RA, rheumatoid arthritis; UCTD, 
undifferentiated connective tissue disease.Available online http://arthritis-research.com/content/10/5/R123
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A clear correlation between the frequency of IDDM, MS, RA,
SLE, and inflammatory bowel disease (IBD) and the north-
south latitude, sunshine exposure, and vitamin D levels has
been shown [12,35-37]. MS and IBD are diseases prevalent
in Canada, the northern parts of the US, and Europe. The
severity of MS has been shown to fluctuate seasonally, with
exacerbations occurring mostly during the springtime [38,39].
Munger and colleagues [40] found that the risk of MS was
40% lower in women taking more vitamin D. This condition is
explained by the fact that the northern hemisphere receives
less sunlight, especially during the winter. MS, IDDM, and RA
are more prevalent in temperate high latitudes than at the
equatorial latitude. It seems that high vitamin D intake, regard-
less of sunlight exposure, is associated with a reduced risk of
developing IDDM, RA, and MS. A study on 29,000 women
showed that vitamin D intake reduced the risk of developing
RA [41]. Vitamin D supplementation (2,000 IU/day) during
Figure 2
Evolution of undifferentiated connective disease to defined connective  tissue diseases Evolution of undifferentiated connective disease to defined connective 
tissue diseases. MCTD, mixed connective tissue disease; RA, rheuma-
toid arthritis; SLE, systemic lupus erythematosus; UCTD, undifferenti-
ated connective tissue disease.
Table 2
Relationship between low serum levels of vitamin D and clinical/serological manifestations of undifferentiated connective tissue 
disease patients
Correlation between clinical symptoms and vitamin D insufficiency P value OD
(95% CI)
Xerostomia/xerophtalmia 0.8276 0.8909
(0.3768–2.107)
Polyarthritis 0.4834 0.7621
(0.3772–1.540)
Skin lesion 0.0046 2.987
(1.397–6.385)
Pleuritis 0.0346 5.367
(1.078–26.719)
Central and peripheral nervous system manifestations 1 0.8344
(0.1924–3.619)
Raynaud phenomenon 0.5331 0.7407
(0.3178–1.726)
Oesophageal involvement 0.3448 1.650
(0.6569–4.144)
Correlation between antibodies and vitamin D insufficiency
Anti-U1-ribonucleoprotein antibody 0.0240 5.083
(1.286–20.094)
Anti-SSA antibody 0.029 3.474
(1.147–10.520)
Anti-cyclic citrullinated peptide antibody 0.0001 12.0
(3.541–42.036)
Anti-double-stranded DNA antibody 0.2551 0.4896
(0.1751–1.369)
Anti-neutrophil cytoplasmic antibody 0.2978 0.4024
(0.064–2.51)
Anti-cardiolipin antibody 0.3728 1.715
(0.6535–4.501)
Anti-SSB antibody 0.2945 0.5254
(0.1484–1.860)
OD, Odds ratio; CI, confidence intervalArthritis Research & Therapy    Vol 10 No 5    Zold et al.
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infancy also significantly reduced the subsequent develop-
ment of IDDM, evaluated 30 years later [12]. Vitamin D defi-
ciency is common in patients with Crohn disease even when
the disease is in remission [42].
25(OH)D3, 1,25(OH)2D3, and PTH levels in 25 Caucasian
SLE patients (disease duration of 1 to 8 years) and in 25
female patients with fibromyalgia were studied, and no signifi-
cant difference between the two groups was found [43].
Müller and colleagues [44] assessed the levels of 25(OH)D3
and 1,25(OH)2D3 in 21 SLE patients, 29 RA patients, and 12
osteoarthritis patients and found that vitamin D levels in SLE
patients were significantly lower compared with patients with
osteoarthritis and controls [44]. Significantly lower serum
25(OH)D3 levels were found among 123 recently diagnosed
SLE patients compared with 240 age- and gender-matched
controls from the Carolina Lupus Study [13]. Levels of
25(OH)D3 were significantly lower among African-Americans
compared with Caucasians. Levels of vitamin D were highest
in the summer and lowest in the winter. Vitamin D deficiency
was found in 18% of the SLE patients with the presence of
severe renal disease and photosensitivity [13].
In our results, the probability to develop dermatological symp-
toms (photosensitivity, vasculitis, and erythema) and pleuritis
correlated with vitamin D insufficiency. The presence of anti-
U1-RNP, anti-SSA, and anti-CCP occurred more frequently in
these particular patients.
Data in our study as well as those reported by others suggest
that UCTD may develop into any well-defined CTDs [16-18].
Evolution into a specific established CTD was found in 21.7%
of patients with UCTD during the follow-up period. UCTD
most frequently progressed into RA, and SLE, Sjögren syn-
drome, and MCTD had about the same prevalence. Interest-
ingly, the lowest levels of vitamin D (<30 ng/mL) were
measured in UCTD patients who subsequently evolved to
defined CTDs. In our previous study, we found the shift toward
Th1 with increased IFN-γ production in patients with UCTD
combined with the degree of immunoregulatory disturbances
characterized by the progressive divergent shifts in natural and
induced T-regulatory cell populations [45]. Therefore, immu-
noregulatory abnormality signifies the transition from undiffer-
entiated to definitive CTD [45]. Since vitamin D is an important
regulator of the immune system, it raises the possibility that
vitamin D deficiency may contribute to the progression into
well-defined CTDs.
Several factors can lead to low levels of vitamin D in our
patients with UCTD. Although the physical activity of most
patients was not limited, patients with photosensitive rashes
do seem to have a reduced exposure to sunlight and generally
use very high UV protection. As another vitamin D-reducing
factor, anti-vitamin D antibodies have been described in
patients with SLE, antiphospholipid syndrome, and pemphi-
gus vulgaris, and these autoantibodies were associated with
anti-dsDNA antibodies in SLE [46].
The observed low vitamin D levels underline the importance of
an intensified routine vitamin D supplementation as opposed
to the current administration practice. This is further supported
by a few prospective studies showing that the intake of vitamin
D significantly reduces the incidence and/or progression of
autoimmune diseases [40,47,48].
Based on our findings, we conclude that the measurement of
serum vitamin D is crucial in UCTD patients and that the effec-
tive supplementation of vitamin D may be important in these
patients. Future prospective studies are needed to determine
the efficacy of supplementation of vitamin D in the prevention
of the subsequent evolution of UCTD to well-defined CTDs
and to establish the role of vitamin D in the treatment of
autoimmune diseases.
Conclusions
Vitamin D has a pivotal role in the maintenance of immune
homeostasis. In various systemic autoimmune diseases, low
levels of vitamin D have been described previously. We
showed that, in patients with UCTD, serum levels of vitamin D
were significantly lower compared with healthy individuals.
Moreover, critically low levels of the vitamin clearly correlated
with the progression to well-established CTDs. Our findings
Table 3
Comparison of 35 patients who developed established connective tissue disease with 126 patients who remained in the stable 
stage of undifferentiated connective tissue disease
Patients with evolution into defined CTD
n = 35
Patients with 'stable' UCTD
n = 126
P value
Age, years (mean ± standard deviation) 43.85 ± 11.1
range: 21–67
44.9 ± 12.7
range: 17–78
0.651
Duration of follow-up, years 2.31 ± 1.2
range: 0.5–4
4.09 ± 2.36
range: 0.5–9
0.0006113
Vitamin D serum levels, ng/mL 14.7 ± 6.45
range: 4.7–25.2
33.0 ± 13.4
range: 6–88.9
0.0001
CTD, connective tissue disease; UCTD, undifferentiated connective tissue disease.Available online http://arthritis-research.com/content/10/5/R123
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support the idea that vitamin D may be a key regulator of
autoimmune processes in patients with UCTD.
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